Concepedia

Author

Pamela J. Cheshire

St. Jude Children's Research Hospital

Also Known As

P J Cheshire, P. J. Cheshire, P.J. Cheshire, Pamela Cheshire, Pamela J Cheshire, Pamela J. Cheshire

40

Publications

2.6K

Citations

25

H-Index

50

Concepts

All Affiliations

St. Jude Children's Research HospitalSt Bartholomew's HospitalQueen Mary University of LondonUniversity of Tennessee Health Science CenterDuke Medical Center
PJ

About

Pamela J. Cheshire is an author at St. Jude Children's Research Hospital specializing in medicine, tumor biology, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

21

28

2.1K

2

Cell Biology

9

9

612

3

Health Sciences

2

2

35

4

Natural Sciences

2

2

235

5

Biochemistry

2

2

329

Pamela J. Cheshire

×

33

Publications

2.6K

Citations

25

H-Index

YearCitations

Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

Peter J. Houghton, Pamela J. Cheshire, James D. Hallman,

Cancer Chemotherapy and Pharmacology

1995

406

Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.

Lorina Dudkin, Michael B. Dilling, Pamela J. Cheshire,

PubMed

2001

232

Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors

Peter J. Houghton, Pamela J. Cheshire, Leann Myers,

Cancer Chemotherapy and Pharmacology

1992

229

Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice

Clinton F. Stewart, Markos Leggas, John D. Schuetz,

Cancer Research

2004

199

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.

Peter J. Houghton, Pamela J. Cheshire, James C. Hallman,

PubMed

1993

161

Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.

Peter J. Houghton, Clinton F. Stewart, Pamela J. Cheshire,

PubMed

2000

138

Relationship Between Topotecan Systemic Exposure and Tumor Response in Human Neuroblastoma Xenografts

William C. Zamboni, Clinton F. Stewart, Peter J. Houghton,

JNCI Journal of the National Cancer Institute

1998

135

Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.

Joyce Thompson, William C. Zamboni, Pamela J. Cheshire,

PubMed

1997

125

Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy.

Mary K. Danks, Christopher L. Morton, E J Krull,

PubMed

1999

97

Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.

Joyce Thompson, E. Olusegun George, Catherine A. Poquette,

PubMed

1999

86

Page 1